Fewer than 4 out of 10 adults received influenza vaccinations last winter, the lowest rate in 7 seasons; methamphetamine use is rising across the United States, but it is overshadowed by opioids and fatal overdoses; tobacco giant Altria will stop selling e-cigarette “pods” and will pull almost all its flavored products from the market in an attempt to help curb teen vaping.
Fewer than 4 out of 10 adults received influenza vaccinations last winter, the lowest rate in 7 seasons, The Washington Post reported. The CDC said it is a likely reason that the 2017-2018 season was the deadliest in decades. Vaccination coverage among adults was 37.1%, a decrease of 6.2 percentage points from the previous season.
Methamphetamine use is rising across the United States, but it is overshadowed by opioids and fatal overdoses, NPR reported. The drug is stronger and cheaper than it used to be, and is now the product of Mexican drug cartels that are mass-producing high-quality quantities of the drug and pushing it into markets where it was previously unknown. Even in rural communities ravaged by decades of experience with the drug, meth is on the upswing thanks to its relatively low price, availability, and a shortage of treatment options.
Tobacco giant Altria will stop selling e-cigarette “pods” and will pull almost all its flavored products from the market in an attempt to help curb teen vaping. The Hill noted that e-cigarettes make up just a fraction of Altria’s sales, so it has much less to lose than a company like dominant player Juul, which only makes e-cigarettes. Altria, which makes Marlboro and Virginia Slim cigarettes, also said it supports federal legislation to raise the legal smoking age to 21. The company is the first to pull the pods as the FDA is cracking down on e-cigarette manufacturers amid a huge increase in teen vaping.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
November 10th 2023In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen
Untangling Medical Debt From Credit Scores: Effects So Far and Next Steps
November 29th 2023After recent policy changes removing most medical debts from credit reports, Americans are seeing their credit scores increase, but experts warn of the need to monitor billing and collection practices for unintended consequences.
Read More